New research commissioned by Milton Park reveals that £2.14 billion of equity investment was generated across 272 companies based in the science, technology and business community over the past decade.
The facility has been designed by Foster + Partners and is devoted to reimagining and redefining cancer treatment whilst enhancing overall human health and global health policy.
There are significant opportunities for investors to meet growing demand from the life sciences sector, according to the 2023 Europe Life Sciences Cluster Outlook published by JLL – a leading real estate and investment management firm.
The early-stage drug discovery company with operations in Oxford and Boston is looking to increase its drug discovery and validation capabilities in key neuro disease areas.
The funding will help to develop a unique solution that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the chance of cancer regrowth.
The funding, over the next five years, was awarded to Oxford’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).
The study analysed samples from 300 patients with non-specific but concerning symptoms of cancer, and their results show that cancer was correctly detected in 19 out of every 20 patients with cancer using this test.
The researchers believe their work could help compress vaccine development timelines to 100 days from pathogen identification to mass production and distribution.
The research, by scientists at the Rosalind Franklin Institute, has shown that nanobodies generated by llamas and camels can effectively target the SARS-CoV-2 virus that causes COVID-19.
The funding will allow The Oxford Trust to commence the conversion of dedicated high spec laboratory facilities with 3,000 sq ft of laboratory and close to 9,000 sq ft of allied space.
The study concludes that there are increased risks of some haematological and vascular adverse events following vaccination, but the risks are substantially higher following a coronavirus infection.
Led by Blue Venture Fund, the new funding will accelerate Oxford-based Ultromics’ use of AI-enabled echocardiograms to improve patient outcomes.